Compare Robinhood Markets, Inc. (HOOD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Merck & Co., Inc. — how do they compare? Robinhood Markets, Inc. trades at $109.1 (market cap $96.21B), while Merck & Co., Inc. trades at $145.61 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.7× Robinhood Markets, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Merck & Co., Inc. for 98 Days on average.
| HOOD | MRK | |
|---|---|---|
Market Cap | $96.21B | $351.28B |
Volume | 22,572,153 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $152.46 | $156.43 |
52-Week Low | $65.16 | $82.49 |
Typical Hold Time | 75 Days | 98 Days |
Enterprise Value | $102.75B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $108.95, down 0.51% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation ratios like P/E of 47.35 are elevated. Recent news highlights expansion into 24/7 stock trading and AI-driven features, signaling growth initiatives.
Outlook remains positive with a consensus price target of $137.53, offering ~26% upside, but risks include high valuation sensitivity and competitive pressures in the brokerage sector. Earnings beat in two of the last three quarters supports growth trajectory, though investors should monitor execution on new product launches and regulatory developments.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
